View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

About ZOMETA: defend against SREs across a broad range of tumour types

About ZOMETA
Renal Cell Carcinoma
ZOMETA reduces SREs

Page

1 2

ZOMETA^® effectively helps to protect patients with renal cell carcinoma from the threat of SREs

Efficacy of ZOMETA vs placebo in patients with advanced renal cell carcinoma²

NR=not reached.

ZOMETA significantly extended time to first SRE vs placebo (median not reached vs 72 days, P=.006)²
ZOMETA reduced the percentage of patients who experienced an SRE by 50% vs placebo (P=.015)²

ZOMETA can delay and reduce SREs in patients with renal cell carcinoma and bone metastases²

Page

1 2

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

ZOMETA® effectively helps to protect patients with renal cell carcinoma from the threat of SREs

ZOMETA can delay and reduce SREs in patients with renal cell carcinoma and bone metastases2

ZOMETA^® effectively helps to protect patients with renal cell carcinoma from the threat of SREs

ZOMETA can delay and reduce SREs in patients with renal cell carcinoma and bone metastases²